[Neurotrophic mechanisms of psychedelic therapy].

Biol Aujourdhui

CNRS ERL 3649 « Neuroplasticité et thérapies des addictions », UMR-S 1124, Université Paris Descartes, 4, avenue de l'Observatoire, 75006 Paris, France.

Published: May 2020

Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules. Serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are gaining attention as potential treatments for depression and addiction, similarly to 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD), and ibogaine for addiction. Although they possess distinct pharmacological profiles, their kinetics of action are quite similar: the therapeutic effects are felt within the hours following administration, and last well beyond drug elimination by the organism. This strongly suggests the induction of neurogenic and plastic mechanisms, including the involvement of trophic factors. This review will explore the literature dealing with the effects of psychedelics on neurotrophins, as well as the plastic adaptations that they induce, in an attempt to understand their surprising therapeutic potential. We will show that although ketamine and serotonergic psychedelics have affinity for very different receptors (NMDA, 5-HT2A), they ultimately initiate similar plastic adaptations in the prefrontal cortex through the involvement of the brain-derived neurotrophic factor (BDNF). We will see that although MDMA uses the same receptors as serotonergic psychedelics to alleviate PTSD symptoms, its effect on BDNF levels seem paradoxical and quite different. Finally, we show how ibogaine could exert its anti-addictive properties through a completely different neurotrophic factor than other psychedelic drugs, the glial cell line-derived neurotrophic factor (GDNF). While the current literature concerning the psychiatric applications of psychedelic therapy is encouraging, it remains to be determined whether their benefits could be obtained without their psychotomimetic effects, or concerns over potential toxicity.

Download full-text PDF

Source
http://dx.doi.org/10.1051/jbio/2019015DOI Listing

Publication Analysis

Top Keywords

serotonergic psychedelics
12
neurotrophic factor
12
psychedelic drugs
8
plastic adaptations
8
effects
5
[neurotrophic mechanisms
4
psychedelic
4
mechanisms psychedelic
4
psychedelic therapy]
4
therapy] psychedelic
4

Similar Publications

Nutmeg and mace are commonly known for their medicinal and culinary properties. The chemical compounds found in nutmeg and mace, notably myristicin, elemicin, and safrole, have been implicated in the psychoactive and anticholinergic effects that are the result of acute toxicity. Cases of mace toxicity are not as commonly reported as nutmeg toxicity.

View Article and Find Full Text PDF

[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].

Nervenarzt

January 2025

Abteilung für Molekulares Neuroimaging, Zentralinstitut für Seelische Gesundheit, Medizinische Fakultät Mannheim, Universität Heidelberg, 68159, Mannheim, Deutschland.

Background: Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology.

Objective: What could be the shared effects of various antidepressants and in this context what role do extrapharmacological factors, such as the body and environment, play?

Material And Method: The available literature on clinical and preclinical data for assumed combined active factors of serotonergic psychedelic drugs, (es)ketamine, monoaminergic antidepressants and zuranolone are presented and the influence of context factors on the individual mechanisms of action is discussed.

Results: There are many indications that classical and novel pharmacological approaches could share similar mechanisms of action in the treatment of depression.

View Article and Find Full Text PDF

Purpose Of Review: Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed.

View Article and Find Full Text PDF

Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.

ACS Med Chem Lett

January 2025

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.

View Article and Find Full Text PDF

Purpose Of Review: Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!